BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35121073)

  • 1. The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness).
    El Sharouni MA; Rawson RV; Sigurdsson V; Witkamp AJ; van Gils CH; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
    J Am Acad Dermatol; 2022 Aug; 87(2):298-305. PubMed ID: 35121073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma.
    El Sharouni MA; Aivazian K; Witkamp AJ; Sigurdsson V; van Gils CH; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
    JAMA Dermatol; 2021 Feb; 157(2):166-173. PubMed ID: 33355600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
    Wat H; Senthilselvan A; Salopek TG
    J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel node status predicts survival in thick melanomas: the Oxford perspective.
    Rughani MG; Swan MC; Adams TS; Marshall A; Asher R; Cassell OC; Middleton MR
    Eur J Surg Oncol; 2012 Oct; 38(10):936-42. PubMed ID: 22617251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis and Management of Thick and Ultrathick Melanoma.
    Blakely AM; Cohen JT; Comissiong DS; Vezeridis MP; Miner TJ
    Am J Clin Oncol; 2019 Nov; 42(11):824-829. PubMed ID: 31517636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanomas in children and adolescents: Clinicopathologic features and survival outcomes.
    El Sharouni MA; Rawson RV; Potter AJ; Paver EC; Wilmott JS; Witkamp AJ; Sigurdsson V; van Diest PJ; Scolyer RA; Thompson JF; Lo SN; van Gils CH
    J Am Acad Dermatol; 2023 Mar; 88(3):609-616. PubMed ID: 36509217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.
    El Sharouni MA; Stodell MD; Ahmed T; Suijkerbuijk KPM; Cust AE; Witkamp AJ; Sigurdsson V; van Diest PJ; Scolyer RA; Thompson JF; van Gils CH; Lo SN
    Ann Oncol; 2021 Mar; 32(3):375-383. PubMed ID: 33253862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging.
    Dodds TJ; Lo S; Jackett L; Nieweg O; Thompson JF; Scolyer RA
    Am J Surg Pathol; 2018 Mar; 42(3):359-366. PubMed ID: 29240580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Patuzzo R; Mattavelli I; Gallino G; Galeone C; Valeri B; Mocellin S; Del Fiore P; Ribero S; Mandalà M; Tauceri F; Lombardo M; Maurichi A;
    Cancer; 2023 Aug; 129(15):2331-2340. PubMed ID: 37162404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
    Fairbairn NG; Orfaniotis G; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thick melanomas without lymph node metastases: A forgotten group with poor prognosis.
    El Sharouni MA; Witkamp AJ; Sigurdsson V; van Diest PJ; Suijkerbuijk KPM
    Eur J Surg Oncol; 2020 May; 46(5):918-923. PubMed ID: 31901365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
    Yamamoto M; Fisher KJ; Wong JY; Koscso JM; Konstantinovic MA; Govsyeyev N; Messina JL; Sarnaik AA; Cruse CW; Gonzalez RJ; Sondak VK; Zager JS
    Cancer; 2015 May; 121(10):1628-36. PubMed ID: 25677366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (>4 mm) cutaneous melanoma: an observational study.
    Morera-Sendra N; Tejera-Vaquerizo A; Traves V; Requena C; Bolumar I; Pla A; Vázquez C; Soriano V; Nagore E
    Eur J Dermatol; 2016; 26(1):34-48. PubMed ID: 27023017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of sentinel lymph node biopsy compared with that of Breslow thickness: implications for informed consent in patients with invasive melanoma.
    Freeman SR; Gibbs BB; Brodland DG; Zitelli JA
    Dermatol Surg; 2013 Dec; 39(12):1800-12. PubMed ID: 24299573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic variables in patients with thick melanomas. Analysis of 362 cases.
    Aguilar-Romero E; Chávez-Hernández JD; Zepeda-Najar C; Salcedo-Hernández RA; Lino-Silva LS
    Gac Med Mex; 2021; 157(2):207-211. PubMed ID: 34270542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node status affects long-term survival in patients with intermediate-thickness melanoma.
    G Lben K; Berberoğlu U; Altınyollar H; Kınaş V; Turanlı S
    J Cancer Res Ther; 2016; 12(2):840-4. PubMed ID: 27461661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.